Automated quantitative analysis of DCC tumor suppressor protein in ovarian cancer tissue microarray shows association with β-catenin levels and outcome in patients with epithelial ovarian cancer

Annals of Oncology

Volumn 17, Issue 12, 2006, Pages 1797-1802

  Bamias, A ^a,d   Yu, Z ^b   Weinberger, P M ^b   Markakis, S ^c   Kowalski, D ^b   Camp, R L ^b   Rimm, D L ^b   Dimopoulos, M A ^a   Psyrri, A ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ALEXANDRA HOSPITAL   (Greece)

^d NONE   (Greece)

Author keywords

catenin; DCC; Ovarian cancer; Prognosis

Indexed keywords

BETA CATENIN; CA 125 ANTIGEN; CARBOPLATIN; DELETED IN COLORECTAL CANCER PROTEIN; PACLITAXEL; TUMOR SUPPRESSOR PROTEIN;

ADULT; ARTICLE; COMBINATION CHEMOTHERAPY; CYTOREDUCTIVE SURGERY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; STATISTICAL ANALYSIS; TISSUE MICROARRAY; TUMOR SUPPRESSOR GENE;

AUTOMATION; BETA CATENIN; COHORT STUDIES; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENES, DCC; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS;

EID: 33845369401     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl310     Document Type: Article

References (23)

1. Jemal A, Tiwari RC, Murray T et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54: 8-29.
2. Cho KR, Fearon ER. DCC: Linking tumor suppressor genes and altered cell surface interactions in cancer? Eur J Cancer 1995; 31A: 1055-1060.
3. Uchino S, Tsuda H, Noguchi M et al. Frequent loss of heterozygosity at the DCC locus in gastric cancer. Cancer Res 1992; 52: 3099-3102.
4. Fang DC, Jess JR, Wang DX. Loss of heterozygosity and loss of expression of the DCC gene in gastric cancer. J Clin Pathol 1998; 51: 593-596.
5. Cropp CS, Lidereau R, Campbell G et al. Loss of heterozygosity on chromosome 17 and 18 in breast carcinoma: Two additional regions identified. Proc Natl Acad Sci U S A 1990; 87: 7737-7741.
6. Gao X, Honn KV, Grignon D et al. Frequent loss of expression and loss of heterozygosity of putative tumor suppressor gene DCC in prostatic carcinomas. Cancer Res 1993; 353: 2723-2727.
7. Peng HQ, Bailey D, Bronson D et al. Loss of heterozygosity of tumor suppressor genes in testis cancer. Cancer Res 1995; 55: 2871-2875.
8. Jen J, Kim H, Piantadosi Set al. Allelic loss of chromosome 18q and prognosis in coiorectal cancer. N Engl J Med 1994; 331: 213-221.
9. Watanabe T, Tsung-The W, Catalano PJ et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001; 344: 1196-1206.
10. Shibata D, Reale MA, Lavin P et al. The DCC protein and prognosis in colorectal cancer. N Engl J Med 1996; 335: 1727-1732.
11. Sun XF, Rutten S, Zhang H, Nenskjold B. Expression of the deleted in colorectal cancer gene is related to prognosis in DNA diploid and low proliferative colorectal adenocarcinoma. J Clin Oncol 1999; 17: 1745-1750.
12. Fujita M, Enomoto T, Murata Y. Genetic alterations in ovarian carcinoma: with specific reference to histological subtypes. Mol Cell Endocrinol 2003; 202: 97-99.
13. Takakura S, Okamoto A, Saito M et al. Allelic imbalance in chromosome band 18q21 and SMAD4 mutations in ovaraina cancers. Genes Chromosomes Cancer 1999; 24: 264-271.
14. Chenevix-Trench G, Leary J, Kerr J et al. Frequent loss of heterozygosity on chromosome 18 in ovarian adenocarcinoma, which does not always include the DCC locus. Oncogene 1992; 7: 1059-1065.
15. Saegusa M, Machida D, Okayasu I. Loss of DCC gene expression during ovarian tumorigenesis: Relation to tumor differentiabon and progression. Br J Cancer 2000; 82: 571-578.
16. Lassus H, Salovaara R, Aaltonen LA, Butzow R. Allelic analysis of serous ovarian carcinoma reveals two putative tumor suppressor loci at 18q22-q23 distal to SMAD4, SMAD2, and DCC. Am J Pathol 2001; 159: 35-42.
17. Schwartz DR, Kardia SLR, Shedden KA et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-ptognosis ovarian carcinomas. Cancer Res 2002; 62: 4722-4729.
18. Reyes-Mugica M, Meyerhardt JA, Rzasa J et al. Truncated DCC reduces N-cadherin/catenin expression and calcium-dependent cell adhesion in neuroblastoma cells. Lab Invest 2001; 81: 201-210.
19. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002; 8:1323-1327.
20. Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
21. Psyrri A, Bamias A, Yu Z et al. Subcellular localization and protein levels of cyclin-dependent kinase inhibitor p27 independently predict for survival in epithelial ovarian cancer. Clin Cancer Res 2005; 11: 8384-8390.
22. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: A new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004; 10: 7252-7259.
23. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using 'optimal' cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994; 86: 829-835.